Previous 10 | Next 10 |
European Medicines Agency Grants BioMarin's Request for Accelerated Assessment of Valoctocogene Roxaparvovec for Treatment of Severe Hemophilia A MAA Resubmission on Track for June 2021 PR Newswire SAN RAFAEL, Calif. , May 24, 2021 /PRNewswire/ -- BioMarin Ph...
BioMarin Pharmaceutical (BMRN) announces an update to its Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia A, reported previously.Five-year and four-year post-treatment follow-up of the 6e13 vg/kg and 4e13 vg/kg cohorts...
BioMarin Provides Highlights of 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec with the Longest Duration of Clinical Experience for a Gene Therapy in Hemophilia A All Study Participants in 6e13 vg/kg and 4e13 vg/kg Dose Cohorts Remain off Fac...
Stanley Druckenmiller's Duquesne Family Office takes new stakes in Palantir Technologies (PLTR) with 5.98M shares, Citigroup (C) at 2.12M shares, First Horizon (FHN) with 1.95M shares, and Coupang (CPNG) with 714K shares.Exits Carnival (CCL), Disney (DIS), Elanco Animal Health (ELAN), Nextera...
BioMarin Announces 6 Presentations at American Society of Gene and Cell Therapy (ASGCT) Virtual 2021 Annual Meeting Research Findings are Part of the Largest and Longest Development Program for any Gene Therapy in Hemophilia A and Advance the Scientific Understanding of AAV5 Gen...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Value and recovery stocks have started to climb and shoul...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy outperformed through a rotation out of growt...
BioMarin to Participate in Two Upcoming Virtual Investor Conferences - 7th Annual Truist Securities Life Sciences Summit on May 4 at 1:50pm ET - BofA 2021 Health Care Conference on May 11 at 2:00pm ET PR Newswire SAN RAFAEL, Calif. , May 3, 2021 /PRNewswi...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. A reflation trade begun in November continued, driving a ...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. A sharp market rotation tied to economic reopening caused...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease PR Newswire Now Approved for Children of All Ages with CLN2 Batten Disease, Regardless of Whether They Yet Show Symptoms SAN RAFAEL, C...
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander ...
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...